ABSTRACT
In this article, the epidemiology of hepatocellular carcinoma (HCC), risk factors for the development of HCC, and how these factors affect the decision about whether an individual should or should be entered into a screening program are considered. The factors determining the risk for HCC include age, male gender, and the nature of the underlying liver disease. In particular, cirrhosis is associated with a significant risk for HCC. However, in hepatitis B HCC also occurs in noncirrhotic liver. Decision analysis can be used to identify patients at greatest risk for HCC and who might be candidates for screening. Screening itself should be developed in a programmatic manner to ensure that appropriate target populations are identified, that appropriate screening tests are chosen, and that appropriate recall and enhanced follow-up are instituted for patients who have positive screening test results. Screening should be by ultrasonography at 4- to 12-month intervals. Patients with abnormal screening tests require additional investigation using computed tomography scanning, magnetic resonance imaging, or liver biopsy. Negative results do not exclude the possibility of cancer and further follow-up is necessary.
KEYWORDS
Hepatocellular carcinoma - chronic hepatitis B - chronic hepatitis C - cancer screening
REFERENCES
-
1
Parkin D M, Bray F, Ferlay J, Pisani P.
Estimating the world cancer burden: Globocan 2000.
Int J Cancer.
2001;
94
153-156
-
2 Ferlay J, Bray F, Pisani P, Parkin D M. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0 Lyon, France; IARC Press 2001
-
3 World Health Organization .Mortality database. WHO Statistical Information System Available at: http://www.who.int/whosis 2001
-
4
Bosch F X, Ribes J, Díaz M, Clèries R.
Primary liver cancer: worldwide incidence and trends.
Gastroenterology.
2004;
127(suppl 1)
S5-S16
-
5
McGlynn K A, Tsao L, Hsing A W, Devesa S S, Fraumeni Jr J F.
International trends and patterns of primary liver cancer.
Int J Cancer.
2001;
94
290-296
-
6
Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C.
Increase in primary liver cancer in the UK, 1979-94.
Lancet.
1997;
350
1142-1143
-
7
Okuda K, Fujimoto I, Hanai A, Urano Y.
Changing incidence of hepatocellular carcinoma in Japan.
Cancer Res.
1987;
47
4967-4972
-
8
El-Serag H B, Mason A C.
Rising incidence of hepatocellular carcinoma in the United States.
N Engl J Med.
1999;
340
745-750
-
9
El Serag H B, Davila J A, Petersen N J, McGlynn K A.
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.
Ann Intern Med.
2003;
139
817-823
-
10
Khan S A, Taylor-Robinson S D, Toledano M B, Beck A, Elliott P, Thomas H C.
Changing international trends in mortality rates for liver, biliary and pancreatic tumours.
J Hepatol.
2002;
37
806-813
-
11
Levi F, Lucchini F, Negri E, Boyle P, la Vecchia C.
Cancer Mortality in Europe, 1995-1999, and overview of trends since 1960.
Int J Cancer.
2004;
110
155-169
-
12
Hassan M M, Frome A, Patt Y Z, El-Serag H B.
Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States.
J Clin Gastroenterol.
2002;
35
266-269
-
13
McCredie M, Williams S, Coates M.
Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995.
Br J Cancer.
1999;
79
1277-1282
-
14
King H, Locke F B.
Cancer mortality among Chinese in the United States.
J Natl Cancer Inst.
1980;
65
1141-1148
-
15
Rosenblatt K A, Weiss N S, Schwartz S M.
Liver cancer in Asian migrants to the United States and their descendants.
Cancer Causes Control.
1996;
7
345-350
-
16
Naimark D, Naglie G, Detsky A S.
The meaning of life expectancy: what is a clinically significant gain?.
J Gen Intern Med.
1994;
9
702-707
-
17
Laupacis A, Feeny D, Detsky A S, Tugwell P X.
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
CMAJ.
1992;
146
473-481
-
18
Sarasin F P, Giostra E, Hadengue A.
Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.
Am J Med.
1996;
101
422-434
-
19
Arguedas M R, Chen V K, Eloubeidi M A, Fallon M B.
Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Am J Gastroenterol.
2003;
98
679-690
-
20 Beasley R P, Hwang L Y. Epidemiology of hepatocellular carcinoma in viral hepatitis and liver disease. Vyas AN, Dienstag JL, Hoofuagle JH New York; Grune and Stratton 1984: 209-224
-
21
Beasley R P.
Hepatitis B virus as the etiologic agent in hepatocellular carcinoma.
Hepatology.
1982;
2(suppl)
21-26s
-
22
Sakuma K, Saitoh N, Kasai M et al..
Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.
Hepatology.
1988;
8
1642-1646
-
23
Yu M W, Chang H C, Liaw Y F et al..
Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.
J Natl Cancer Inst.
2000;
92
1159-1164
-
24
Villeneuve J P, Desrochers M, Infante-Rivard C et al..
A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.
Gastroenterology.
1994;
106
1000-1005
-
25
McMahon B J, Alberts S R, Wainwright R B et al..
Hepatitis B-related sequelae: a prospective study of 1400 hepatitis B surface antigen-positive Alaska native carriers.
Arch Intern Med.
1990;
150
1051-1054
-
26
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
-
27
Fattovich G, Brollo L, Giustina G et al..
Natural history and prognostic factors for chronic hepatitis type B.
Gut.
1991;
32
294-298
-
28
de Franchis R, Meucci G, Vecchi M et al..
The natural history of asymptomatic hepatitis B surface antigen carriers.
Ann Intern Med.
1993;
118
191-194
-
29
Sanchez-Tapias J M, Costa J, Mas A et al..
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.
Gastroenterology.
2002;
123
1848-1856
-
30
Kew M C, Marcus R, Geddes E W.
Some characteristics of Mozambican Shangaans with primary hepatocellular cancer.
S Afr Med J.
1977;
51
306-309
-
31
Kew M C, Macerollo P.
Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks.
Gastroenterology.
1988;
94
439-442
-
32
Fattovich G, Giustina G, Degos F et al..
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.
Gastroenterology.
1997;
112
463-472
-
33
Bruix J, Barrera J M, Calvet X et al..
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.
Lancet.
1989;
2
1004-1006
-
34
Niederau C, Lange S, Heintges T et al..
Prognosis of chronic hepatitis C: results of a large, prospective cohort study.
Hepatology.
1998;
28
1687-1695
-
35
Degos F, Christidis C, Ganne-Carrie N et al..
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.
Gut.
2000;
47
131-136
-
36
Sun C A, Wu D M, Lin C C et al..
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan.
Am J Epidemiol.
2003;
157
674-682
-
37
Bruix J, Sherman M, Llovet J M et al..
Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000- EASL conference.
J Hepatol.
2001;
35
421-430
-
38
Ganne-Carrie N, Chastang C, Chapel F et al..
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.
Hepatology.
1996;
23
1112-1118
-
39
Velazquez R F, Rodriguez M, Navascues C A et al..
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.
Hepatology.
2003;
37
520-527
-
40
Moriyama M, Matsumura H, Aoki H et al..
Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.
Intervirology.
2003;
46
296-307
-
41
Hassan M M, Hwang L Y, Hatten C J et al..
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.
Hepatology.
2002;
36
1206-1213
-
42
Schoniger-Hekele M, Muller C, Kutilek M et al..
Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.
Eur J Gastroenterol Hepatol.
2000;
12
941-948
-
43
El Serag H B, Mason A C.
Risk factors for the rising rates of primary liver cancer in the United States.
Arch Intern Med.
2000;
160
3227-3230
-
44
Adami H O, Chow W H, Nyren O et al..
Excess risk of primary liver cancer in patients with diabetes mellitus.
J Natl Cancer Inst.
1996;
88
1472-1477
-
45
Bugianesi E, Leone N, Vanni E et al..
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
Gastroenterology.
2002;
123
134-140
-
46
Elmberg M, Hultcrantz R, Ekbom A et al..
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives.
Gastroenterology.
2003;
125
1733-1741
-
47
Hsing A W, McLaughlin J K, Olsen J H, Mellemkjar L, Wacholder S, Fraumeni Jr J F.
Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark.
Int J Cancer.
1995;
60
160-162
-
48
Fracanzani A L, Conte D, Fraquelli M et al..
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease.
Hepatology.
2001;
33
647-651
-
49
Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J.
Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis.
Am J Gastroenterol.
2001;
96
1160-1163
-
50
Elzouki A N, Eriksson S.
Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?.
Eur J Gastroenterol Hepatol.
1996;
8
989-994
-
51
Eriksson S, Carlson J, Velez R.
Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.
N Engl J Med.
1986;
314
736-739
-
52
Giordano T P, Kramer J R, Souchek J, Richardson P, El-Serag H B.
Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001.
Arch Intern Med.
2004;
164
2349-2354
-
53
Rosenthal E, Poiree M, Pradier C et al..
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).
AIDS.
2003;
17
1803-1809
-
54
Niederau C, Heintges T, Lange S et al..
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
N Engl J Med.
1996;
334
1422-1427
-
55
Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W.
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP).
Hepatology.
1997;
26
1338-1342
-
56
Fattovich G, Giustina G, Sanchez-Tapias J et al..
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).
Am J Gastroenterol.
1998;
93
896-900
-
57
Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F.
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
Hepatology.
1999;
29
971-975
-
58
Yuen M F, Hui C K, Cheng C C, Wu C H, Lai Y P, Lai C L.
Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Hepatology.
2001;
34
139-145
-
59
Liaw Y F, Sung J J, Chow W C et al..
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
N Engl J Med.
2004;
351
1521-1531
-
60
Nishiguchi S, Shiomi S, Nakatani S et al..
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
Lancet.
2001;
357
196-197
-
61
Valla D C, Chevallier M, Marcellin P et al..
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
Hepatology.
1999;
29
1870-1875
-
62
Camma C, Giunta M, Andreone P, Craxi A.
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
J Hepatol.
2001;
34
593-602
-
63
Hayashi K, Kumada T, Nakano S et al..
Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy.
Hepatogastroenterology.
2002;
49
508-512
-
64
Ikeda K, Saitoh S, Kobayashi M et al..
Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
J Gastroenterol Hepatol.
2001;
16
406-415
-
65
Tanaka H, Tsukuma H, Kasahara A et al..
Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Int J Cancer.
2000;
87
741-749
-
66
Okanoue T, Itoh Y, Minami M et al..
Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.
J Hepatol.
1999;
30
653-659
-
67
Yoshida H, Shiratori Y, Moriyama M et al..
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Ann Intern Med.
1999;
131
174-181
-
68
Toyoda H, Kumada T, Nakano S et al..
Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
Oncology.
2001;
61
134-142
-
69
Valla D C, Degos F.
Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus.
J Hepatol.
2001;
34
606-609
-
70
Oka H, Tamori A, Kuroki T et al..
Prospective study of alpha-foetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma.
Hepatology.
1994;
19
61-66
-
71
Zhang J Y, Wang X, Han S G, Zhuang H.
A case-control study of risk factors for hepatocellular carcinoma in Henan, China.
Am J Trop Med Hyg.
1998;
59
947-951
-
72
Hytiroglou P, Theise N D, Schwartz M et al..
Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature.
Hepatology.
1995;
21
703-708
-
73
Donato M F, Arosio E, Del Ninno E et al..
High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.
Hepatology.
2001;
34
523-528
-
74
Tiniakos D G, Brunt E M.
Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study.
Liver.
1999;
19
58-68
-
75
Ballardini G, Groff P, Zoli M et al..
Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation.
J Hepatol.
1994;
20
218-222
-
76
Borzio M, Trere D, Borzio F et al..
Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.
Mol Pathol.
1998;
51
96-101
-
77
Welch H G, Schwartz L M, Woloshin S.
Do increased 5-year survival rates in prostate cancer indicate better outcomes?.
JAMA.
2000;
284
2053-2055
-
78
McMahon B J, Bulkow L, Harpster A et al..
Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.
Hepatology.
2000;
32
842-846
-
79
Wong L L, Limm W M, Severino R, Wong L M.
Improved survival with screening for hepatocellular carcinoma.
Liver Transpl.
2000;
6
320-325
-
80
Oka H, Kurioka N, Kim K et al..
Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis.
Hepatology.
1990;
12
680-687
-
81
Bolondi L, Sofia S, Siringo S et al..
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis.
Gut.
2001;
48
251-259
-
82
Liu J H, Chen P W, Asch S M et al..
Surgery for hepatocellular carcinoma: does it improve survival?.
Ann Surg Oncol.
2004;
11
298-303
-
83
Llovet J M, Bru C, Bruix J.
Prognosis of hepatocellular carcinoma: the BCLC staging classification.
Semin Liver Dis.
1999;
19
329-338
-
84
Yamamoto J, Iwatsuki S, Kosuge T et al..
Should hepatomas be treated with hepatic resection or transplantation?.
Cancer.
1999;
86
1151-1158
-
85
Molmenti E P, Marsh J W, Dvorchik I et al..
Hepatobiliary malignancies. Primary hepatic malignant neoplasms.
Surg Clin North Am.
1999;
79
43-57
, viii
-
86
Llovet J M, Burroughs A, Bruix J.
Hepatocellular carcinoma.
Lancet.
2003;
362
1907-1917
-
87
Bismuth H, Majno P E, Adam R.
Liver transplantation for hepatocellular carcinoma.
Semin Liver Dis.
1999;
19
311-322
-
88
Michel J, Suc B, Montpeyroux F et al..
Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis.
J Hepatol.
1997;
26
1274-1280
-
89
Llovet J M, Bruix J, Gores G J.
Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy.
Hepatology.
2000;
31
1019-1021
-
90
Yao F Y, Ferrell L, Bass N M et al..
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.
Hepatology.
2001;
33
1394-1403
-
91
Fletcher R H.
Carcinoembryonic antigen.
Ann Intern Med.
1986;
104
66-73
-
92
Sullivan-Pepe M, Etzioni R, Feng Z et al..
Phases of biomarker development for early detection of cancer.
J Natl Cancer Inst.
2001;
93
1054-1061
-
93
Sherman M, Peltekian K M, Lee C.
Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology.
1995;
22
432-438
-
94
Trevisani F, D'Intino P E, Morselli-Labate A M et al..
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.
J Hepatol.
2001;
34
570-575
-
95
Pateron D, Ganne N, Trinchet J C et al..
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.
J Hepatol.
1994;
20
65-71
-
96
Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E.
Efficacy of a surveillance program for early detection of hepatocellular carcinoma.
Cancer.
1996;
78
977-985
-
97
Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T.
Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
Hepatogastroenterology.
1995;
42
387-393
-
98
Sherman M.
Alphafetoprotein: an obituary.
J Hepatol.
2001;
34
603-605
-
99
Grazi G L, Mazziotti A, Legnani C et al..
The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
Liver Transpl Surg.
1995;
1
249-255
-
100
Tsai S L, Huang G T, Yang P M, Sheu J C, Sung J L, Chen D S.
Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma.
Hepatology.
1990;
11
481-488
-
101
Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T.
Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Cancer.
1994;
73
2464-2471
-
102
Marrero J A, Su G L, Wei W et al..
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients.
Hepatology.
2003;
37
1114-1121
-
103
Koike Y, Shiratori Y, Sato S et al..
Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.
Cancer.
2001;
91
561-569
-
104
Sato Y, Nakata K, Kato Y et al..
Early recognition of hepatocellular carcinoma based on altered profiles of alpha-foetoprotein.
N Engl J Med.
1993;
328
1802-1806
-
105
Kumada T, Nakano S, Takeda I et al..
Clinical utility of Lens culinaris agglutinin-reactive alpha-foetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis.
J Hepatol.
1999;
30
125-130
-
106
Shiraki K, Takase K, Tameda Y et al..
A clinical study of lectin-reactive alpha-foetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients.
Hepatology.
1995;
22
802-807
-
107
Taketa K, Endo Y, Sekiya C et al..
A collaborative study for the evaluation of lectin-reactive alpha-foetoproteins in early detection of hepatocellular carcinoma.
Cancer Res.
1993;
53
5419-5423
-
108
Hayashi K, Kumada T, Nakano S et al..
Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-foetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma.
Am J Gastroenterol.
1999;
94
3028-3033
-
109
Okuda K, Tanaka M, Kanazawa N et al..
Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by Lens culinaris agglutinin-reactive alpha-foetoprotein.
Int J Oncol.
1999;
14
265-271
-
110
Chen T H, Chen C J, Yen M F et al..
Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.
Int J Cancer.
2002;
98
257-261
-
111
Larcos G, Sorokopud H, Berry G, Farrell G C.
Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.
AJR Am J Roentgenol.
1998;
171
433-435
-
112 Bartolozzi C, Lencioni R. In: Bartolozzi C, Lencioni R Liver Malignancies. Diagnostic and Interventional Radiology Berlin; Springer-Verlag 1999
-
113
Takayasu K, Moriyama N, Muramatsu Y et al..
The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients.
AJR Am J Roentgenol.
1990;
155
49-54
-
114
Zhang B, Yang B.
Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.
J Med Screen.
1999;
6
108-110
-
115
Miller W J, Baron R L, Dodd III G D, Federle M P.
Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients.
Radiology.
1994;
193
645-650
-
116
Kobayashi K, Sugimoto T, Makino H et al..
Screening methods for early detection of hepatocellular carcinoma.
Hepatology.
1985;
5
1100-1105
-
117
Sangiovanni A, Del Ninno E, Fasani P et al..
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.
Gastroenterology.
2004;
126
1005-1014
-
118
Santagostino E, Colombo M, Rivi M et al..
A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.
Blood.
2003;
102
78-82
Dr.
Morris Sherman
Toronto General Hospital, 200 Elizabeth Street, Toronto
Ont M5G 2C4 Canada
Email: morris.sherman@uhn.on.ca
